S8 Ep14: Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL
Dr Hilal discusses data with frontline ibrutinib, acalabrutinib, and zanubrutinib in chronic lymphocytic leukemia; remaining uncertainties regarding the use of BTK inhibitors to manage this disease; and how a patient’s minimal residual disease status influences their subsequent treatment options.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.